NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03675737,Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859),https://clinicaltrials.gov/study/NCT03675737,,COMPLETED,"The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in combination with chemotherapy (Cisplatin combined with 5-Fluorouracil \[FP regimen\] or oxaliplatin combined with capecitabine \[CAPOX regimen\]) versus placebo in combination with chemotherapy (FP or CAPOX regimens) in the treatment of human epidermal growth factor receptor 2 (HER2) negative advanced gastric or GEJ adenocarcinoma in adult participants.

The primary hypotheses of this study are that pembrolizumab plus chemotherapy is superior to placebo plus chemotherapy in terms of overall survival (OS).",YES,Stomach Neoplasms,BIOLOGICAL: Pembrolizumab|DRUG: Cisplatin|DRUG: 5-fluorouracil|DRUG: oxaliplatin|DRUG: capecitabine|DRUG: Placebo for Pembrolizumab,"Overall Survival (OS) in All Participants, OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. OS was estimated using the product-limit (Kaplan-Meier) method for censored data., Up to 45.9 months|Overall Survival (OS) In Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1, OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. OS was estimated using the product-limit (Kaplan-Meier) method for censored data., Up to 45.9 months|Overall Survival (OS) In Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10, OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. OS was estimated using the product-limit (Kaplan-Meier) method for censored data., Up to 45.9 months","Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in All Participants, PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1 as assessed by BICR, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. PFS was estimated using the product-limit (Kaplan-Meier) method for censored data., Up to 49.5 months|Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1, PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1 as assessed by BICR, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. PFS was estimated using the product-limit (Kaplan-Meier) method for censored data., Up to 49.5 months|Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10, PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1 as assessed by BICR, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. PFS was estimated using the product-limit (Kaplan-Meier) method for censored data., Up to 49.5 months|Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in All Participants, ORR was defined as the percentage of the participants who had a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD) according to RECIST 1.1 as assessed by BICR., Up to 49.5 months|Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1, ORR was defined as the percentage of the participants who had a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD) according to RECIST 1.1 as assessed by BICR., Up to 49.5 months|Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10, ORR was defined as the percentage of the participants who had a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD) according to RECIST 1.1 as assessed by BICR., Up to 49.5 months|Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in All Participants, DOR was defined as the time from first documented evidence of a confirmed Complete Response (CR) or Partial Response (PR) until progressive disease (PD) or death, whichever occurred first. Per RECIST 1.1 as assessed by BICR, CR was the disappearance of all target lesions and PR was ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. PD was defined as ≥20% increase in the SOD of target lesions according to RECIST 1.1. In addition to the relative increase of 20%, the SOD must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. DOR for participants who had not progressed or died at the time of analysis was censored at the date of the last tumor assessment. DOR was estimated using the product-limit (Kaplan-Meier) method for censored data., Up to 49.5 months|Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1, DOR was defined as the time from first documented evidence of a confirmed Complete Response (CR) or Partial Response (PR) until progressive disease (PD) or death, whichever occurred first. Per RECIST 1.1 as assessed by BICR, CR was the disappearance of all target lesions and PR was ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. PD was defined as ≥20% increase in the SOD of target lesions according to RECIST 1.1. In addition to the relative increase of 20%, the SOD must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. DOR for participants who had not progressed or died at the time of analysis was censored at the date of the last tumor assessment. DOR was estimated using the product-limit (Kaplan-Meier) method for censored data., Up to 49.5 months|Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10, DOR was defined as the time from first documented evidence of a confirmed Complete Response (CR) or Partial Response (PR) until progressive disease (PD) or death, whichever occurred first. Per RECIST 1.1 as assessed by BICR, CR was the disappearance of all target lesions and PR was ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. PD was defined as ≥20% increase in the SOD of target lesions according to RECIST 1.1. In addition to the relative increase of 20%, the SOD must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. DOR for participants who had not progressed or died at the time of analysis was censored at the date of the last tumor assessment. DOR was estimated using the product-limit (Kaplan-Meier) method for censored data., Up to 49.5 months|Number of Participants Who Experienced an Adverse Event (AE), An AE was defined as any untoward medical occurrence, in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants with at least one AE is presented., Up to 36.7 months|Number of Participants Who Discontinued Study Treatment Due To an Adverse Event (AE), An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued study treatment due to an AE is presented., Up to 33.7 months",,Merck Sharp & Dohme LLC,,ALL,"ADULT, OLDER_ADULT",PHASE3,1579,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",3475-859|MK-3475-859|KEYNOTE-859|JAPIC-CTI|2023-508890-10|2018-001757-27,2018-11-08,2022-10-03,2025-03-03,2018-09-18,2023-10-12,2025-03-25,"UCLA Hematology/Oncology - Westwood (Building 200 Suite 120) ( Site 0124), Los Angeles, California, 90095, United States|UC Irvine Health/Division of Hematology Oncology, Dept of Medicine ( Site 0128), Orange, California, 92868, United States|University of Miami, Sylvester Comprehensive Cancer Center ( Site 0113), Miami, Florida, 33136, United States|Greater Baltimore Medical Center ( Site 0102), Baltimore, Maryland, 21204, United States|Minnesota Oncology Hematology, PA ( Site 8000), Minneapolis, Minnesota, 55404, United States|University of Rochester ( Site 0122), Rochester, New York, 14642, United States|Cancer Treatment Centers of America - Philadelphia ( Site 0112), Philadelphia, Pennsylvania, 19124, United States|Allegheny General Hospital ( Site 0118), Pittsburgh, Pennsylvania, 15212, United States|Oncology & Hematology Assoc. SW Virginia, Inc., DBA Blue Ridge Cancer Care ( Site 8001), Roanoke, Virginia, 24014, United States|Wenatchee Valley Clinic [Wenatchee, WA] ( Site 0116), Wenatchee, Washington, 98801, United States|Instituto Medico Alexander Fleming ( Site 0307), Buenos Aires, Caba, C1426ANZ, Argentina|Instituto de Investigaciones Metabolicas ( Site 0312), Buenos Aires, C1012AAR, Argentina|Fundacion Favaloro - Hospital Universitario ( Site 0302), Buenos Aires, C1093AAS, Argentina|Centro Oncologico Riojano Integral ( Site 0313), La Rioja, F5300COE, Argentina|Instituto San Marcos ( Site 0311), San Juan, J5400EBB, Argentina|Liverpool Hospital ( Site 2301), Liverpool, New South Wales, 2170, Australia|Southern Medical Day Care Centre ( Site 2303), Wollongong, New South Wales, 2500, Australia|Box Hill Hospital ( Site 2300), Box Hill, Victoria, 3128, Australia|Instituto do Cancer do Ceara ( Site 0407), Fortaleza, Ceara, 60430-230, Brazil|CIONC - Centro Integrado de Oncologia de Curitiba ( Site 0405), Curitiba, Parana, 80810-050, Brazil|Hospital de Caridade de Ijui ( Site 0402), Ijui, Rio Grande Do Sul, 98700 000, Brazil|Hospital Nossa Senhora da Conceicao ( Site 0403), Porto Alegre, Rio Grande Do Sul, 91350-200, Brazil|CEPON - Centro de Pesquisas Oncologicas ( Site 0400), Florianopolis, Santa Catarina, 88034-000, Brazil|Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0401), Rio de Janeiro, 20231-050, Brazil|IBCC - Instituto Brasileiro de Controle do Cancer ( Site 0404), Sao Paulo, 03102-002, Brazil|BC Cancer - Abbotsford ( Site 0206), Abbotsford, British Columbia, V2S 0C2, Canada|Sunnybrook Research Institute ( Site 0202), Toronto, Ontario, M4N 3M5, Canada|Princess Margaret Cancer Centre ( Site 0203), Toronto, Ontario, M5G 2M9, Canada|McGill University Health Centre ( Site 0208), Montreal, Quebec, H4A 3J1, Canada|Instituto Clinico Oncologico del Sur ( Site 0500), Temuco, Araucania, 4810469, Chile|Fundacion Arturo Lopez Perez FALP ( Site 0501), Santiago, Region M. De Santiago, 7500921, Chile|Sociedad Oncovida S.A. ( Site 0508), Santiago, Region M. De Santiago, 7510032, Chile|Pontificia Universidad Catolica de Chile ( Site 0502), Santiago, Region M. De Santiago, 7620002, Chile|Cancer Hospital Chinese Academy of Medical Sciences ( Site 2421), Beijing, Beijing, 100021, China|Peking Union Medical College Hospital ( Site 2425), Beijing, Beijing, 100730, China|Fujian Medical University Union Hospital ( Site 2410), Fuzhou, Fujian, 350001, China|Fujian Provincial Cancer Hospital ( Site 2414), Fuzhou, Fujian, 350014, China|900 Hospital of the Joint ( Site 2418), Fuzhou, Fujian, 350025, China|The First Affiliated Hospital of Xiamen University ( Site 2430), Xiamen, Fujian, 361003, China|Zhongshan Hospital Xiamen University ( Site 2447), Xiamen, Fujian, 361004, China|Guangdong General Hospital ( Site 2431), Guangzhou, Guangdong, 510080, China|Peking University Shenzhen Hospital ( Site 2442), Shenzhen, Guangdong, 518036, China|Fourth Hospital Of Hebei Medical University ( Site 2436), Shijiazhuang, Hebei, 050011, China|Harbin Medical University Cancer Hospital ( Site 2401), Harbin, Heilongjiang, 150081, China|Henan Cancer Hospital ( Site 2415), Zhengzhou, Henan, 450008, China|Hubei Cancer Hospital ( Site 2434), Wuhan, Hubei, 430079, China|Xiangya Hospital Central-South University ( Site 2419), Changsha, Hunan, 410008, China|Hunan Cancer Hospital ( Site 2439), Changsha, Hunan, 410013, China|Changzhou Cancer Hospital-Changzhou Fourth Peoples Hospital ( Site 2441), Changzhou, Jiangsu, 213032, China|The 81st Hospital of PLA ( Site 2413), Nanjing, Jiangsu, 210002, China|Jiangsu Cancer Hospital ( Site 2432), Nanjing, Jiangsu, 210009, China|Yancheng First People s Hospital ( Site 2426), Yancheng, Jiangsu, 224000, China|The First Affiliated Hospital of Nanchang University ( Site 2440), Nanchang, Jiangxi, 330006, China|The First Hospital of Jilin University ( Site 2416), Chang chun, Jilin, 130021, China|The Affiliated Hospital of Qingdao University ( Site 2405), Qingdao, Shandong, 266061, China|Shanghai East Hospital ( Site 2403), Shanghai, Shanghai, 200120, China|Zhongshan Hospital affiliated to Fudan University ( Site 2407), Shanghai, Shanghai, 210000, China|1st Affil hosp of Med College of Xi'an Jiaotong University ( Site 2428), XiAn, Shanxi, 710061, China|Cancer Hospital Affiliated to Xinjiang Medical University ( Site 2420), Urumqi, Xinjiang, 830001, China|Zhejiang Provincial People's Hospital ( Site 2446), Hangzhou, Zhejiang, 310014, China|Sir Run Run Show Hospital ( Site 2427), Hangzhou, Zhejiang, 310016, China|Zhejiang Cancer Hospital ( Site 2417), Hangzhou, Zhejiang, 310022, China|Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 0608), Valledupar, Cesar, 200001, Colombia|Oncomedica S.A. ( Site 0606), Monteria, Cordoba, 230002, Colombia|Instituto Nacional de Cancerologia E.S.E ( Site 0605), Bogota, Distrito Capital De Bogota, 110321, Colombia|Centro Medico Imbanaco de Cali S.A ( Site 0604), Cali, Valle Del Cauca, 760042, Colombia|CIMCA Centro de Investigacion y Manejo del Cancer ( Site 3001), San Jose, 10103, Costa Rica|Policlinico San Bosco ( Site 3002), San Jose, 10103, Costa Rica|ICIMED - Instituto de Investigacion en Ciencias Medicas ( Site 3000), San Jose, 10108, Costa Rica|Masarykuv onkologicky ustav ( Site 3103), Brno, Jihomoravsky Kraj, 65653, Czechia|FN Ostrava ( Site 3105), Ostrava, Moravskoslezsky Kraj, 708 52, Czechia|Fakultni nemocnice Plzen ( Site 3102), Plzen, Plzensky Kraj, 304 60, Czechia|Nemocnice AGEL Novy Jicin a.s. ( Site 3104), Novy Jicin, 74101, Czechia|Fakultni nemocnice Olomouc ( Site 3100), Olomouc, 779 00, Czechia|Fakultni Thomayerova nemocnice ( Site 3101), Praha 4, 140 59, Czechia|Rigshospitalet ( Site 3202), Copenhagen, Hovedstaden, 2100, Denmark|Aalborg University Hospital ( Site 3204), Aalborg, Nordjylland, 9000, Denmark|Odense Universitets Hospital ( Site 3201), Odense, Syddanmark, 5000, Denmark|CHU de Rouen ( Site 1006), Rouen, Ain, 76000, France|CHU-Jean Minjoz ( Site 1002), Besancon, Doubs, 25030, France|C.H.R.U. de Brest - Hopital Morvan ( Site 1007), Brest, Finistere, 29200, France|Centre Oscar Lambret ( Site 1003), Lille, Nord, 59000, France|Institut de Cancerologie de l Ouest Centre Rene Gauducheau ( Site 1004), Saint-Herblain, Val-de-Marne, 44805, France|Institut Gustave Roussy ( Site 1000), Villejuif, Val-de-Marne, 94805, France|CHU Hopital Saint Antoine ( Site 1001), Paris, 75012, France|SLK-Kliniken Heilbronn ( Site 1104), Heilbronn, Baden-Wurttemberg, 74078, Germany|Universitaetsklinikum Leipzig ( Site 1114), Leipzig, Sachsen, 04103, Germany|Charite Universitaetsmedizin Berlin ( Site 1101), Berlin, 13353, Germany|Facharztzentrum Eppendorf ( Site 1121), Hamburg, 20249, Germany|Asklepios Klinik Altona ( Site 1100), Hamburg, 22763, Germany|Celan SA ( Site 0705), Guatemala, 01010, Guatemala|Oncomedica ( Site 0702), Guatemala, 01010, Guatemala|Grupo Angeles SA ( Site 0701), Guatemala, 01015, Guatemala|MEDI-K CAYALA ( Site 0704), Guatemala, 01016, Guatemala|Centro Regional de Sub Especialidades Medicas SA ( Site 0703), Quetzaltenango, 09001, Guatemala|Prince of Wales Hospital ( Site 2503), Hong Kong, Hong Kong|Princess Margaret Hospital. ( Site 2502), Hong Kong, Hong Kong|Queen Mary Hospital ( Site 2501), Hong Kong, Hong Kong|Bacs-Kiskun Megyei Korhaz ( Site 3306), Kecskemet, Bacs-Kiskun, 6000, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Gyula Korhaz-Rendelointezet ( Site 3302), Szolnok, Jasz-Nagykun-Szolnok, 5004, Hungary|Semmelweis Egyetem.. ( Site 3305), Budapest, 1083, Hungary|Orszagos Onkologiai Intezet ( Site 3303), Budapest, 1122, Hungary|University of Debrecen Medical Center Clinic of Oncology ( Site 3300), Debrecen, 4032, Hungary|St. James s Hospital ( Site 1200), Dublin, D08 W9RT, Ireland|Beaumont Hospital ( Site 2101), Dublin, D09V2N0, Ireland|Tallaght University Hospital ( Site 1202), Dublin, D24 NR0A, Ireland|Chaim Sheba Medical Center ( Site 1304), Ramat Gan, Tel Aviv, 5266202, Israel|Edith Wolfson Medical Center ( Site 1307), Holon, Tell Abib, 5822012, Israel|Sourasky Medical Center ( Site 1306), Tel Aviv, Tell Abib, 6423906, Israel|Hadassah Ein Karem Jerusalem ( Site 1301), Jerusalem, Yerushalayim, 9112001, Israel|Soroka University Medical Center ( Site 1305), Beer Sheva, 8410101, Israel|Rambam Medical Center ( Site 1303), Haifa, 3109601, Israel|Meir Medical Center ( Site 1308), Kfar Saba, 4428164, Israel|Rabin Medical Center ( Site 1302), Petah Tikva, 4941492, Israel|Istituto Europeo di Oncologia ( Site 1411), Milano, Lombardia, 20141, Italy|Istituto Nazionale dei Tumori Fondazione IRCSS ( Site 1402), Milano, 20133, Italy|Istituto Oncologico Veneto ( Site 1412), Padova, 35128, Italy|Azienda Ospedaliera San Camillo Forlanini ( Site 1413), Roma, 00152, Italy|Aichi Cancer Center Hospital ( Site 2619), Nagoya, Aichi, 464-8681, Japan|National Cancer Center Hospital East ( Site 2617), Kashiwa, Chiba, 277-8577, Japan|Hyogo Cancer Center ( Site 2604), Akashi, Hyogo, 673-8558, Japan|Kobe City Medical Center General Hospital ( Site 2603), Kobe, Hyogo, 650-0047, Japan|Ibaraki Prefectural Central Hospital ( Site 2610), Kasama, Ibaraki, 309-1793, Japan|Kagawa University Hospital ( Site 2615), Kita-gun, Kagawa, 761-0793, Japan|Kitasato University Hospital ( Site 2618), Sagamihara, Kanagawa, 252-0375, Japan|Kanagawa Cancer Center ( Site 2614), Yokohama, Kanagawa, 241-8515, Japan|Kansai Medical University Hospital ( Site 2608), Hirakata, Osaka, 573-1191, Japan|Kindai University Hospital ( Site 2616), Osakasayama, Osaka, 589-8511, Japan|Osaka University Hospital ( Site 2600), Suita, Osaka, 565-0871, Japan|Saitama Cancer Center ( Site 2601), Kitaadachi-gun, Saitama, 362-0806, Japan|National Hospital Organization Kyushu Cancer Center ( Site 2612), Fukuoka, 811-1395, Japan|Hiroshima City Hiroshima Citizens Hospital ( Site 2611), Hiroshima, 730-8518, Japan|Kumamoto University Hospital ( Site 2602), Kumamoto, 860-8556, Japan|Niigata Cancer Center Hospital ( Site 2613), Niigata, 951-8566, Japan|Osaka International Cancer Institute ( Site 2607), Osaka, 541-8567, Japan|National Cancer Center Hospital ( Site 2606), Tokyo, 104-0045, Japan|Tokyo Metropolitan Komagome Hospital ( Site 2605), Tokyo, 113-8677, Japan|The Cancer Institute Hospital of JFCR ( Site 2609), Tokyo, 135-8550, Japan|Seoul National University Hospital ( Site 2803), Seoul, 03080, Korea, Republic of|Severance Hospital Yonsei University Health System ( Site 2800), Seoul, 03722, Korea, Republic of|Asan Medical Center ( Site 2802), Seoul, 05505, Korea, Republic of|Samsung Medical Center ( Site 2801), Seoul, 06351, Korea, Republic of|Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 0808), Guadalajara, Jalisco, 44280, Mexico|Christus Muguerza Clinica Vidriera ( Site 0802), Monterrey, Nuevo Leon, 64570, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran ( Site 0806), Ciudad de Mexico, 14080, Mexico|Medical Care and Research S.A. de C.V. ( Site 0809), Merida, 97070, Mexico|Instituto Nacional de Cancerologia. ( Site 0804), Mexico City, 14080, Mexico|Auckland City Hospital ( Site 2700), Auckland, Northland, 1023, New Zealand|Clinica Ricardo Palma Instituto de Oncologia y Radioterapia ( Site 0908), Lima, 15036, Peru|Instituto Nacional de Enfermedades Neoplasicas ( Site 0901), Lima, 15038, Peru|Hospital Nacional Arzobispo Loayza ( Site 0902), Lima, 15082, Peru|Clinica San Gabriel ( Site 0907), Lima, 15088, Peru|Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego ( Site 1506), Wroclaw, Dolnoslaskie, 50-556, Poland|Dolnoslaskie Centrum Onkologii we Wroclawiu ( Site 1504), Wroclaw, Dolnoslaskie, 53-413, Poland|Szpital Uniwersytecki w Krakowie ( Site 1503), Krakow, Malopolskie, 31-501, Poland|Magodent Szpital Elblaska ( Site 1509), Warszawa, Mazowieckie, 01-748, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (, Warszawa, Mazowieckie, 02-781, Poland|Przychodnia Lekarska Komed ( Site 1514), Konin, Wielkopolskie, 62-500, Poland|Regionalny Szpital Specjalistyczny im Wl. Bieganskiego w Grudziadzu ( Site 1505), Grudziadz, 86-300, Poland|Chelyabinsk Regional Clinical Oncology Dispensary-Chemotherapy ( Site 1608), Chelyabinsk, Chelyabinskaya Oblast, 454087, Russian Federation|SBHI Leningrad Regional Clinical Hospital ( Site 1616), Saint Petersburg, Leningradskaya Oblast, 194291, Russian Federation|Blokhin National Medical Oncology ( Site 1604), Moscow, Moskva, 115478, Russian Federation|Central Clinical Hospital with Polyclinic ( Site 1614), Moscow, Moskva, 121359, Russian Federation|SBHI Samara Regional Clinical Oncology Dispensary ( Site 1609), Samara, Samarskaya Oblast, 443031, Russian Federation|City Clinical Oncology Center ( Site 1603), Saint Petersburg, Sankt-Peterburg, 198255, Russian Federation|Cancer Care Langenhoven Drive Oncology Centre ( Site 1708), Port Elizabeth, Eastern Cape, 6045, South Africa|Universitas Annex National Hospital ( Site 1701), Bloemfontein, Free State, 9301, South Africa|Sandton Oncology Medical Group PTY LTD ( Site 1700), Johannesburg, Gauteng, 2196, South Africa|Wits Clinical Research ( Site 1707), Parktown-Johannesburg, Gauteng, 2193, South Africa|Tshwane District Hospital ( Site 1702), Pretoria, Gauteng, 0002, South Africa|The Oncology Centre Overport and Umhlanga ( Site 1705), Durban, Kwazulu-Natal, 4091, South Africa|Cancercare Rondebosch Oncology ( Site 1709), Cape Town, Western Cape, 7700, South Africa|Groote Schuur Hospital ( Site 1706), Cape Town, Western Cape, 7925, South Africa|Outeniqua Cancercare Oncology Unit ( Site 1704), George, Western Cape, 6530, South Africa|Cape Town Oncology Trials Pty Ltd ( Site 1703), Kraaifontein, Western Cape, 7570, South Africa|Hospital General Universitario de Elche ( Site 1803), Elche, Alicante, 03203, Spain|Hospital Universitario General de Asturias ( Site 1802), Oviedo, Asturias, 33011, Spain|Institut Catala d Oncologia Hospital Germans Trias i Pujol ( Site 1806), Badalona, Barcelona, 08916, Spain|Hospital Universitario Marques de Valdecilla ( Site 1804), Santander, Cantabria, 39008, Spain|HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 1805), Pozuelo de Alarcon, Madrid, 28223, Spain|Hospital General Universitari Vall d Hebron ( Site 1801), Barcelona, 08035, Spain|Universitaetsspital Basel ( Site 1900), Basel, Basel-Stadt, 4056, Switzerland|Hopitaux Universitaires de Geneve HUG ( Site 1907), Geneva, Geneve, 1211, Switzerland|Kantonsspital Graubuenden ( Site 1903), Chur, Grisons, 7000, Switzerland|Kantonsspital St. Gallen ( Site 1901), St. Gallen, Sankt Gallen, 9007, Switzerland|Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 1905), Bellinzona, Ticino, 6500, Switzerland|Universitaetsspital Zuerich ( Site 1902), Zuerich, Zurich, 8091, Switzerland|Luzern Kantonsspital ( Site 1904), Luzern, 6000, Switzerland|Chang Gung Medical Foundation. Kaohsiung Branch ( Site 2902), Kaohsiung, 83301, Taiwan|National Cheng Kung University Hospital ( Site 2901), Tainan, 70457, Taiwan|National Taiwan University Hospital ( Site 2900), Taipei, 100225, Taiwan|Mackay Memorial Hospital ( Site 2903), Taipei, 104, Taiwan|Adana Sehir Hastanesi ( Site 2002), Adana, 01370, Turkey|Hacettepe University Medical Faculty ( Site 2017), Ankara, 06100, Turkey|Abdurrahman Yurtaslan Onkoloji Egitim ve Arastirma Hastanesi ( Site 2006), Ankara, 06200, Turkey|Trakya Universitesi Tip Fakultesi ( Site 2015), Edirne, 22030, Turkey|Ataturk Universitesi Tip Fakultesi Hastanesi ( Site 2000), Erzurum, 25240, Turkey|Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 2001), Istanbul, 34098, Turkey|Dokuz Eylul Universitesi Tip Fakultesi Hastanesi ( Site 2011), Izmir, 35340, Turkey|Malatya Inonu Universitesi Tip Fakultesi Hastanesi ( Site 2009), Malatya, 44280, Turkey|Sakarya Universitesi Egitim ve Arastirma Hastanesi ( Site 2012), Sakarya, 54000, Turkey|City Clinical Hosp.4 of DCC ( Site 2201), Dnipro, Dnipropetrovska Oblast, 49102, Ukraine|MI Kryviy Rih Center of Dnipropetrovsk Regional Council ( Site 2200), Kryviy Rih, Dnipropetrovska Oblast, 50048, Ukraine|MI Precarpathian Clinical Oncology Center ( Site 2204), Ivano-Frankivsk, Ivano-Frankivska Oblast, 76018, Ukraine|Communal non profit enterprise Regional Clinical Oncology Center ( Site 2208), Kharkiv, Kharkivska Oblast, 61070, Ukraine|Clinic of National Cancer Institute ( Site 2203), Kyiv, Kyivska Oblast, 03022, Ukraine|Medical and Diagnostic Centre LLC Dobryi Prognoz ( Site 2205), Kyiv, Kyivska Oblast, 03126, Ukraine|Lviv State Oncology Regional Treatment and Diagnostic Center ( Site 2210), Lviv, Lvivska Oblast, 79031, Ukraine|MI Odessa Regional Oncological Centre ( Site 2212), Odesa, Odeska Oblast, 65055, Ukraine|Medical Centre LLC Oncolife ( Site 2202), Zaporizhzhya, Zaporizka Oblast, 69104, Ukraine|Kyiv City Clinical Oncology Centre ( Site 2213), Kyiv, 03115, Ukraine|South Devon Healthcare Foundation Trust. Torbay Hospital ( Site 1205), Torquay, Devon, TQ2 7AA, United Kingdom|Castle Hill Hospital ( Site 1201), Cottingham, East Riding Of Yorkshire, HU16 5JQ, United Kingdom|University College London Hospital ( Site 1211), London, London, City Of, NW1 2PG, United Kingdom|St. Georges University Hospital NHS Foundation Trust ( Site 1204), London, London, City Of, SW17 0QT, United Kingdom","Study Protocol and Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/37/NCT03675737/Prot_SAP_000.pdf"
